Results 41 to 50 of about 1,547 (116)

Real-world clinical outcomes and treatment response in complement inhibitor experienced and naïve PNH patients prescribed pegcetacoplan in Europe and Canada

Hematology
Objectives This study investigated outcomes and response to pegcetacoplan in complement inhibitor naïve (CInaïve) and experienced (CIexp) PNH patients.Methods Data were drawn from the Adelphi PNH Disease Specific Programme™, a cross-sectional survey of ...
Jens Panse, Juan Carlos Vallejo Llamas, Koo Wilson, Zalmai Hakimi, Barbara Czech, Brianne Kerr, Sam Williamson, Yasmin Taylor, Niall Hatchell, Christopher J. Patriquin   +9 more
doaj   +1 more source

Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy Over 24 Months [PDF]

IMPORTANCE: Despite widespread availability and consensus on its advantages for detailed imaging of geographic atrophy (GA), spectral-domain optical coherence tomography (SD-OCT) might benefit from automated quantitative OCT analyses in GA diagnosis ...
Glinton, Sophie, Scheibler, Lukas, Moghul, Ismail, Faes, Livia, Balaskas, Konstantinos, Bagga, Pallavi, Naik, Gunjan, Ioannidou, Estelle, Keane, Pearse A, Fu, Dun Jack, Patel, Praveen J, Pontikos, Nikolas, Ribeiro Reis, Ana Paula, Liefers, Bart, McKeown, Alex, Lima, Rosana, Wignall, Georgina   +16 more
core   +4 more sources

Geographic Atrophy: Pathophysiology, Diagnosis and Current and Emerging Treatments

TNOA Journal of Ophthalmic Science and Research
Background: Geographic atrophy (GA) is an advanced, irreversible form of age-related macular degeneration (AMD) characterised by progressive loss of photoreceptors, retinal pigment epithelium (RPE) and choriocapillaris.
Alexander G. Maloof, Ava R. James, Nicholas V. Pavic, Shane Zhang, Marcus Pannu, Stephanie Wu, Christohper Go   +6 more
doaj   +1 more source

Impact of Baseline Characteristics on Geographic Atrophy Progression in the FILLY Trial Evaluating the Complement C3 Inhibitor Pegcetacoplan

, 2021
Purpose: To evaluate the effect of select baseline characteristics on geographic atrophy (GA) progression in eyes receiving intravitreal pegcetacoplan or sham. Design: Phase 2 multicenter, randomized, single-masked, sham-controlled trial.
Hamdani, M, Pearce, Ian, Saroj, N, Monés, J, Steinle, NC, Rosenfeld, PJ, Steinle, Nathan C, Metlapally, Ravi, Pearce, I, Ribeiro, R, Ribeiro, Ramiro, Metlapally, R, Hamdani, Mohamed, Lad, EM, Monés, Jordi, Saroj, Namrata, Rosenfeld, Philip J, Lad, Eleonora M   +17 more
core   +1 more source

Plain language summary: treatment of paroxysmal nocturnal hemoglobinuria with pegcetacoplan for 48 weeks (PEGASUS study)

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, serious blood disease, characterized by uncontrolled activation of the complement system that causes hemolysis (destruction of red blood cells). The complement component 5 (C5) inhibitor eculizumab was
Griffin, M, Risitano, A, Castro, CD, Usuki, K, de Latour, RP, Röth, A, Kiladjian, JJ, Al-Adhami, M, Panse, J, Deschatelets, P, Weitz, I, Höchsmann, B, Szer, J, Francois, C, Hillmen, P, Nishimori, H   +15 more
core   +1 more source

Mapping the EORTC QLQ-C30 onto the EQ-5D-5L index for patients with paroxysmal nocturnal hemoglobinuria in France

Journal of Comparative Effectiveness Research, 2023
Aim: To map patient-level data collected on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC) QLQ-C30 to EQ-5D-5L data for estimating health-state utilities in patients with paroxysmal nocturnal ...
Piotr Wojciechowski, Marlena Wdowiak, Zalmai Hakimi, Koo Wilson, Jesse Fishman, Jameel Nazir, Mondher Toumi   +6 more
doaj   +1 more source

Modeling pegcetacoplan treatment effect for atrophic age-related macular degeneration with AI-based progression prediction

International Journal of Retina and Vitreous
Background To illustrate the treatment effect of Pegcetacoplan for atrophy secondary to age-related macular degeneration (AMD), on an individualized topographic progression prediction basis, using a deep learning model.
Irmela Mantel, Romina M. Lasagni Vitar, Sandro De Zanet   +2 more
doaj   +1 more source

Targeted treatment with pegcetacoplan for adolescents with C3G or primary (idiopathic) IC-MPGN in the VALIANT phase 3 trial [PDF]

Targeted treatment; Pegcetacoplan; C3 glomerulopathyTratamiento dirigido; Pegcetacoplan; Glomerulopatía C3Tractament dirigit; Pegcetacoplan; Glomerulopatia C3Background: C3 glomerulopathy (C3G) and primary (idiopathic) immune complex ...
Dixon, Bradley, Greenbaum, Larry, Borovitz, Yael, Licht, Christoph, Ariceta Iraola, Gema, Vivarelli, Marina   +5 more
core   +1 more source

Pegcetacoplan: el primer tratamiento para la DMAE seca aprobado por la FDA

, 2023
Pegcetacoplan, el primer tratamiento para la atrofia geográfica (GA), secundaria a la forma avanzada de degeneración macular (DMAE) seca relacionada con la edad, fue aprobado el pasado 17 de febrero por la Administración de Alimentos y Medicamentos ...
Vidal Gil, Lorena
core   +1 more source

Real-World Experience with Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy in Age-Related Macular Degeneration

To report on the real-world experience of using intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) in age-related macular degeneration (AMD). Retrospective interventional case series.
Beqiri, Sara, Trivizki, Omer, Kumar, Sivathanu, Berni, Alessandro, Liu, Jeremy, O'Brien, Robert C, Yehoshua, Zohar, Gregori, Giovanni, Zhang, Yi, Kastner, James, Nicola, Maura Di, Herrera, Gissel, Le, Viet Hoan, Wang, Ruikang K, Shen, Mengxi, Dubovy, Sander R, Hiya, Farhan, Cheng, Yuxuan, El-Mulki, Omar S, Rosenfeld, Philip J   +19 more
core   +1 more source